Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation into psychiatric clinical practice

Acta Psychiatrica Scandinavica

Volumn 125, Issue 3, 2012, Pages 228-237

  Jurgens G ^a,b   Jacobsen, C B ^c   Rasmussen, H B ^b   Werge, T ^b   Nordentoft, M ^b   Andersen, S E ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c Dansk Sundhedsinstitut   (Denmark)

Author keywords

CYP2C19; CYP2D6; Psychiatry

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; PSYCHOTROPIC AGENT;

ADULT; ARTICLE; CLINICAL PRACTICE; DIAGNOSTIC TEST; DRUG CONCENTRATION; DRUG METABOLISM; DRUG MONITORING; ELECTRONIC MEDICAL RECORD; ETHNOGRAPHY; FEMALE; GENOTYPE; HEALTH CARE DELIVERY; HOSPITAL DISCHARGE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL HEALTH CARE; MENTAL HEALTH CENTER; PARTICIPANT OBSERVATION; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHIATRY; QUALITATIVE ANALYSIS; TREATMENT RESPONSE; WORKFLOW;

ANTHROPOLOGY, CULTURAL; ARYL HYDROCARBON HYDROXYLASES; ATTITUDE OF HEALTH PERSONNEL; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; MENTAL DISORDERS; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS; POLYMORPHISM, GENETIC; PSYCHIATRY; RETROSPECTIVE STUDIES;

EID: 84856954426     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2011.01802.x     Document Type: Article

References (33)

1. Crescenti A, Mas S, Gasso P, Parellada E, Bernardo M, Lafuente A. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy. Clin Exp Pharmacol Physiol 2008;35:807-811.
2. De Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27.
3. Flockhardt DA. Drug interactions: cytochrome P450 drug interaction table, 2007. Available from: [cited 2009 Aug 1].
4. Andreassen OA, Macewan T, Gulbrandsen AK, Mccreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology (Berl) 1997;131:174-179.
5. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997;170:23-26.
6. Rau T, Wohlleben G, Wuttke H et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 2004;75:386-393.
7. Blue Cross and Blue Shield Association Technology Evaluation Center. Special report: genotyping for cytocrome P450 polymorfisms to determine drug metabolizer status, 2004.
8. Fleeman N, Mcleod C, Bagust A et al. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess 2010;14:1-157.
9. Wood M, Ferlie E, Fitzgerald L. Archiving clinical behaviour change: a case of becoming indeterminate. Soc Sci Med 1998;47:1729-1738.
10. Corkindale D, Ward H, Mckinnon R. Low adoption of pharmacogenetic testing: an exploration and explanation of the reasons in Australia. Per Med 2007;4:191-199.
11. Fargher EA, Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics 2005;23:299-314.
12. Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics 2005;15:365-369.
13. Grosse SD, Khoury MJ. What is the clinical utility of genetic testing? Genet Med 2006;8:448-450.
14. Kobylecki CJ, Jakobsen KD, Hansen T, Jakobsen IV, Rasmussen HB, Werge T. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology 2009;59:222-226.
15. Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E. Two single-tube tetra-primer assays to detect the CYP2C19*2 and *3 alleles of S-mephenytoin hydroxylase. Clin Chem 2001;47:772-774.
16. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996;392:30-34.
17. Den Lokale Lægemiddelkomite, H:S Sct.Hans Hospital. Instruks vedr. genetisk analyse af cytokromP450 i klinisk psykiatri, 2006.
18. Hetherington K. Secondhandness:consumption, disposal, and ansent presence. Environ Plan D 2011;22:157-173.
19. Cohen AP. Participant observation. In: Ellen RF, ed. Ethnographic research. A guide to general conduct. London: Academic Press, 1987:216-229.
20. Stige B, Malterud K, Midtgarden T. Toward an agenda for evaluation of qualitative research. Qual Health Res 2009;19:1504-1516.
21. Law J. After method. Mess in social science research. New York: Routledge, 2004.
22. Timmermans S, Berg M. The practice of medical technology. Sociol Health Illn 2003;25:97-114.
23. Hedgecoe A. The politics of personalised medicine: pharmacogenetics in the clinic. Cambridge: Cambridge University Press, 2004.
24. Rhodes L. The shape of action. In: Lindenbaum M, Lock M, eds. Knowledge, power, practice. Berkley: University of California Press, 1995.
25. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994;151:1409-1416.
26. Jäger M, Riedel M, Obermeier M. Timecourse of antipsycotic treatment response in schizophrenia: results from a naturalistic study in 280 patients. Schizophr Res 2010;118:183-188.
27. Hedgecoe A. Education, ethics and knowledge deficits in clinical pharmacogenetics. Pharmacoeconomics 2007;8:267-270.
28. Kirchheiner J, Brosen K, Dahl ML et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;104:173-192.
29. Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442-473.
30. Kirchheiner J, Muller G, Meineke I, Wernecke KD, Roots I, Brockmoller J. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol 2003;23:459-466.
31. Kirchheiner J, Henckel HB, Meineke I, Roots I, Brockmoller J. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 2004;24:647-652.
32. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46:359-388.
33. Stahl SM. How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. Acta Psychiatr Scand 2010;122:440-441.